VIDEO: Combination venetoclax, azacitidine shows promising efficacy, safety in high-risk MDS
Click Here to Manage Email Alerts
Venetoclax plus azacitidine showed an acceptable safety profile and promising efficacy in older patients with high-risk myelodysplastic syndrome, according to phase 1 data presented at the ASH Annual Meeting and Exposition.
Jacqueline S. Garcia, MD, of the department of medical oncology at Dana-Farber Cancer Institute, reported the updated safety and efficacy of combination venetoclax (Venclexta; AbbVie, Genentech) and azacitidine and the exploratory analysis of key patient-reported outcomes in those who received the recommended phase 2 dose.
“We see here with the 78 patients treated with the combination, the overall response rate was 79% and for a high-risk population that is very encouraging,” Garcia said. “What was notable was for patients that were treated at recommended phase 2 dose, this overall response rate was still captured in roughly 84%. So, we see that there’s durable responses, there’s a high frequency of response and it’s happening early.”
Garcia also discussed exploratory data on patient reported outcomes, which suggest patients are having clinically meaningful improvements in quality of life measures. She noted that these data will be “put in the limelight” when the combination is compared in the randomized setting.
“We’re really due to try to update the standard of care therapy and this early data looks compelling that we have a good agent out there that is a good competitor,” she said.
Collapse
Garcia JS, et al. Abstract 656. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts